2,390 results on '"Younes, Anas"'
Search Results
2. Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
3. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
4. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker
5. Other New Agents for Hodgkin Lymphoma
6. Targeting CD30 in Patients with Hodgkin Lymphoma
7. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
8. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
9. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
10. ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
11. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
12. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
13. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
14. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
15. CROSSWISE Final Report Management & Entrepreneurship
16. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
17. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
18. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
19. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study
20. First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors
21. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
22. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
23. Treatment of Hodgkin lymphoma
24. World Health Organization classification
25. Introduction
26. Staging
27. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
28. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
29. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
30. P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)
31. Other New Agents for Hodgkin Lymphoma
32. Targeting CD30 in Patients with Hodgkin Lymphoma
33. Targeting CD30 in Patients with Hodgkin Lymphoma
34. Other New Agents for Hodgkin Lymphoma
35. Emerging epigenetic-modulating therapies in lymphoma
36. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
37. OncoTree: A Cancer Classification System for Precision Oncology
38. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma
39. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma
40. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
41. Follicular lymphoma
42. Special Statement
43. Introduction by the Guest Editor
44. Novel Agents Targeting Oncogenic Pathways in Lymphoma
45. Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
46. Figure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
47. Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies
48. Supplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
49. Supplementary Tables from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
50. Data from Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.